Quabodepistat

Quabodepistat
Clinical data
Other names	OPC-167832
Drug class	Fluoroquinolone antibiotic
Legal status
Legal status	investigational;
Identifiers
	IUPAC name 5-[[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy]-8-fluoro-3,4-dihydro-1H-quinolin-2-one;
CAS Number	1883747-71-4;
PubChem CID	118904282;
IUPHAR/BPS	13059;
DrugBank	DB17770;
ChemSpider	88298183;
UNII	1PQN78P4S3;
KEGG	D13037;
ChEBI	CHEBI:758664;
ChEMBL	ChEMBL5095080;
Chemical and physical data
Formula	C21H20ClF3N2O4
Molar mass	456.85 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CC(=O)NC2=C(C=CC(=C21)OC[C@@]3(CCN(C[C@H]3O)C4=C(C=C(C=C4F)Cl)F)O)F;
	InChI InChI=InChI=1S/C21H20ClF3N2O4/c22-11-7-14(24)20(15(25)8-11)27-6-5-21(30,17(28)9-27)10-31-16-3-2-13(23)19-12(16)1-4-18(29)26-19/h2-3,7-8,17,28,30H,1,4-6,9-10H2,(H,26,29)/t17-,21-/m1/s1; Key:XZISSTDXPBUCJA-DYESRHJHSA-N;

Quabodepistat is an investigational new drug of the fluoroquinolone antibiotic class that is being evaluated by Otsuka Pharmaceutical for the treatment of tuberculosis. It is a DprE1 enzyme inhibitor.^[1]^[2]^[3] DprE1 is required for the synthesis of arabinogalactan, a component of the tuberculosis cell wall, so inhibiting this enzyme disrupts cell wall construction and therefore kills the bacteria.^[4]

Clinical trials

Quabodepistat is currently in phase 3 clinical trials for tuberculosis.^[5]